Emergence of Lipid-Based Vesicular Carriers as Nanoscale Pharmacotherapy in Rheumatoid Arthritis

Publisher： Bentham Science Publishers

E-ISSN： 1877-9131|5|2|111-121

ISSN： 1877-9123

Source： Recent Patents on Nanomedicine, Vol.5, Iss.2, 2015-01, pp. : 111-121

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Association Between Lipid Levels and Major Adverse Cardiovascular Events in Rheumatoid Arthritis Compared to Non–Rheumatoid Arthritis Patients

By  

ARTHRITIS & RHEUMATOLOGY, Vol. 67, Iss. 8, 2015-05 ,pp. : 2004-2010

John Wiley & Sons Inc

Access to resources Recommend Favorite

Rheumatoid arthritis

By  

Community Practitioner, Vol. 80, Iss. 6, 2007-06 ,pp. : 24-26

Community Practitioner

Access to resources Recommend Favorite

Lipid-Based Nanocarriers for CNS-Targeted Drug Delivery

By  

Recent Patents on CNS Drug Discovery, Vol. 7, Iss. 1, 2012-04 ,pp. : 71-86

Bentham Science Publishers

Access to resources Recommend Favorite

Lipid-Based Systems for Delivery of Biological Macromolecules

By  

Recent Patents on Nanomedicine, Vol. 5, Iss. 2, 2015-01 ,pp. : 96-103

Bentham Science Publishers

Access to resources Recommend Favorite

Potential Mechanisms Leading to the Abnormal Lipid Profile in Patients With Rheumatoid Arthritis Versus Healthy Volunteers and Reversal by Tofacitinib

By  

ARTHRITIS & RHEUMATOLOGY, Vol. 67, Iss. 3, 2015-03 ,pp. : 616-625

John Wiley & Sons Inc

Access to resources Recommend Favorite